Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: A randomized, double-blind, cross-over trial

Background The carbonic anhydrase inhibitor acetazolamide stimulates ventilation through metabolic acidosis mediated by renal bicarbonate excretion. In animal models, acetazolamide attenuates acute hypoxia-induced pulmonary hypertension (PH), but its efficacy in treating patients with PH due to pulm...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	M. Lichtblau, S. Saxer, J. Müller, P. Appenzeller, C. Berlier, S.R. Schneider, L. Mayer, M. Furian, E.I. Schwarz, E.R. Swenson, K.E. Bloch, S. Ulrich
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Taylor & Francis Group 2024-07-01
Σειρά:	Pulmonology
Θέματα:	Acetazolamide Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension Exercise capacity 6-Minute walk distance Pulmonary vascular disease
Διαθέσιμο Online:	https://www.tandfonline.com/doi/10.1016/j.pulmoe.2022.11.004
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!